Marina Baptista

Marina Baptista

Auto-generated profile, based on publicly available information

Marina Baptista

A CBIOS - Research Center for Biosciences and Health Technologies, Universidade Lusófona de Humanidades e Tecnologias , Lisboa, Campo Grande , Lisboa , Portugal and

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2003 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
CPClaire Poyart
Claire Poyart
EPElisabeth Pellegrini
Elisabeth Pellegrini
MMMichael Marceau
Michael Marceau
MBMarina Baptista
Marina Baptista
FJFrancis Jaubert
Francis Jaubert
PTPatrick Trieu‐Cuot
Patrick Trieu‐Cuot
Summary: D‐alanylation of lipoteichoic acid (LTA), allows Gram‐positive bacteria to modulate their surface charge, regulate ligand binding and control the electromechanical properties of the cell wall. In this study, the role of D‐alanyl LTA in the virulence of the extracellular pathogen Streptococcus agalactiae was investigated. We demonstrate that a DltA– isogenic mutant displays an increased susceptibility to host defence peptides such as human defensins and animal‐derived cationic peptides. Accordingly, the mutant strain is more susceptible to killing by mice bone marrow‐derived macrophages and human neutrophils than the wild‐type strain. In addition, the virulence of the DltA– mutant is severely impaired in mouse and neonatal rat models. This mutant was eliminated more rapidly than the wild‐type strain from the lung of three‐week‐old mice inoculated intranasally and, consequently, is unable to induce a pneumonia. Finally, after intravenous injection of three‐week‐old mice, the survival of the DltA– mutant is markedly reduced in the blood in comparison to that of the wild‐type strain. We hypothesize that the decreased virulence of the DltA– mutant is a consequence of its increased susceptibility to cationic antimicrobial peptides and to killing by phagocytes. These results demonstrate that the D‐alanylation of LTA contributes to the virulence of S. agalactiae.

1 July 1997 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
MBMarina Baptista
Marina Baptista
FDFlorence Depardieu
Florence Depardieu
PRPeter Reynolds
Peter Reynolds
PCPatrice Courvalin
Patrice Courvalin
MAMichel Arthur
Michel Arthur
The vanB gene cluster mediates glycopeptide resistance by production of peptidoglycan precursors ending in the depsipeptide D‐alanyl‐D‐lactate (D‐Ala‐D‐Lac) instead of D‐Ala‐D‐Ala found in susceptible enterococci. Synthesis of D‐Ala‐D‐Lac and hydrolysis of D‐Ala‐D‐Ala is controlled by the VanRBSB two‐component regulatory system that activates transcription of the resistance genes in response to vancomycin but not to teicoplanin. Two substitutions (A30→G or D168→Y) in the VanSB sensor kinase resulted in induction by teicoplanin, indicating that the N‐terminal domain of the protein was involved in glycopeptide sensing. A substitution (T237→K) located in the vicinity of the putative autophosphorylation site of VanSB (H233) was associated with a constitutive phenotype and affected a conserved residue known to be critical for the phosphatase activity of related kinases. A mutant producing an impaired host D‐Ala:D‐Ala ligase required vancomycin for growth, since D‐Ala‐D‐Lac was only produced under inducing conditions. The ddl and vanSB mutations, alone or in combination, resulted in various resistance phenotypes that were determined by the amount of D‐Ala‐D‐Ala and D‐Ala‐D‐Lac incorporated into peptidoglycan precursors under different inducing conditions.

1 September 2007 in Microbes and Infection
Verified
Journal Article
Closed access
VMVanessa Magalhães
Vanessa Magalhães
IVIsabel Veiga-Malta
Isabel Veiga-Malta
MAMaria Almeida
Maria Almeida
MBMarina Baptista
Marina Baptista
ARAdília Ribeiro
Adília Ribeiro
PFPaula Ferreira
Paula Ferreira

15 May 2013 in Microscopy and Microanalysis
Verified
Journal Article
Closed access
PDF file
Catarina ReisCatarina Reis
Catarina Reis
AGAna Gomes
Ana Gomes
Patrícia RijoPatrícia Rijo
Patrícia Rijo
SCSara Candeias
Sara Candeias
PPPedro Contreiras Pinto
Pedro Contreiras Pinto
LALia Ascensão
Lia Ascensão
Azelaic acid (AzA) is used in the treatment of acne. However, side effects and low compliance have been associated with several topical treatments with AzA. Nanotechnology presents a strategy that can overcome these problems. Polymeric nanoparticles can control drug release and targeting and reduce local drug toxicity. The aim of this study was to produce and evaluate an innovative topical treatment for acne with AzA-loaded poly-dl-lactide/glycolide copolymer nanoparticles. A soft white powder of nanoparticles was prepared. The mean size of loaded nanoparticles was <400 nm and zeta potential was negative. Spherical nanoparticles were observed by scanning electron microscopy. Encapsulation efficiency was around 80% and a strong interaction between the polymer and the drug was confirmed by differential scanning calorimetric analysis. In vitro drug release studies suggested a controlled and pulsatile release profile. System efficacy tests suggested similar results between the loaded nanoparticles and the nonencapsulated drug against the most common bacteria associated with acne. Cytotoxicity of AzA-loaded nanoparticles was concentration dependent, although not pronounced. The occluded patch test seemed to indicate that the formulation excipients were safe and thus AzA-loaded nanoparticles appear to be an efficient and safe treatment for acne.

1 April 1999 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
MBMarina Baptista
Marina Baptista
PRPierre Rodrigues
Pierre Rodrigues
FDFlorence Depardieu
Florence Depardieu
PCPatrice Courvalin
Patrice Courvalin
MAMichel Arthur
Michel Arthur
The vanB gene cluster confers resistance to vancomycin but not to the related antibiotic teicoplanin, as the VanRBSB two‐component regulatory system triggers expression of the glycopeptide resistance...

8 January 2015 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
Catarina ReisCatarina Reis
Catarina Reis
LRLuís Vasques Roque
Luís Vasques Roque
MBMarina Baptista
Marina Baptista
Patrícia RijoPatrícia Rijo
Patrícia Rijo
Oral candidiasis is a mycosis on the mucous membranes of the mouth but not limited to the mouth. Nystatin is one of the most frequently employed antifungal agents to treat infections and may be safely given orally as well as applied topically but its absorption through mucocutaneous membranes such as the gut and the skin is minimal. The purpose of this study is to enhance the effectiveness of nystatin using particulate system such as beads, micro- and nanoparticles of alginate incorporated into toothpaste. Those particulate systems of nystatin were prepared by extrusion/external gelation for beads and emulsification/internal gelation for micro- and nanoparticles and characterized. Small, anionic charged and monodispersed particles were successfully produced. The type of particulate system influenced all previous parameters, being microparticles the most suitable particulate system of nystatin showing the slowest release, the highest inhibitory effect of Candida albicans over a period of one year. Those results allowed the conclusion that alginate exhibits properties that enable the in vitro functionality of encapsulated nystatin and thus may provide the basis for new successful approaches for the treatment of oral antifungal infections such as oral candidiasis.